Table 1 Symptoms and signs at presentation

Slides:

Advertisements

Similar presentations

Delayed Neurotoxicity The cumulative risk at 5 years to develop overt dementia is 24-30% (1,2). For patients aged >60 year the risk of dementia at 7 years.

Advertisements

ANDREW NG PRINCE OF WALES HOSPITAL Role of primary chemoradiation in esophageal carcinoma.

P449. p450 Figure 15-1 p451 Figure 15-2 p453 Figure 15-2a p453.

Stereotactic Body Radiation Therapy (SBRT): The optimal indication for operable tumors in inoperable patients D.Katsochi 1, S.Kosmidis 1, A.Fotopoulou.

Permanent Interstitial Implants Ideal strategy to curatively manage small volume gynecologic malignancies Can deliver high cumulative radiation dose to.

Time-to-event Basic Medical Statistics Course: Module C October 2010 Wilma Heemsbergen.

Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC randomised trial From.

Palliative Single 8 Gy Radiotherapy for Symptomatic Aggressive Lymphomas 2666 Ａ -408 Oguchi M, Eba J, Tanaka O, Kozuka T, Murofushi K, Toshiyasu T, Tsurugai.

Role of Radiation Therapy in Brain metastasis Bongkot Supawongwattana, M.D. Division of Therapeutic Radiology and Oncology, Faculty of Medicine, Chiang.

Reducing excess imaging dose to cancer patients receiving radiotherapy Adam Schwertner, Justin Guan, Xiaofei Ying, Darrin Pelland, Ann Morris, Ryan Flynn.

Slide 1 Presented By Jan Buckner at 2014 ASCO Annual Meeting.

What Factors Predict Outcome At Relapse After Previous Esophagectomy And Adjuvant Therapy in High-Risk Esophageal Cancer? Edward Yu 1, Patricia Tai 5,

방사선종양학과 - 혈액종양내과 Joint Conference 경희의료원 방사선종양학과 R4 공 문 규.

THE CONNOR MAN FOUNDATION Our mission is to identify and fund research dedicated to finding effective treatment options- and ultimately a cure-for Diffuse.

Non-Hodgkin’s Lymphoma

Department of Radiation Oncology, Tohoku University School of Medicine

Figure 1. Scree plot for the exploratory factor analysis (EFA) of the Death Depression Scale (DDS). From: Development and psychometric evaluation of a.

Fig. 3 Overall and disease-free survival of single-zone metastasis group according to the number of stations involved. No significant differences were.

Pediatric Brain Tumors: The Need for “Pristine” Biologic and Clinical Data Roger J. Packer, MD Senior Vice-President Neuroscience and Behavioral Medicine.

Cancer Hospital & Institute, Chinese Academy of Medical Sciences

Feasibility of hippocampal sparing radiation therapy for glioblastoma using helical Tomotherapy Dr Kamalram THIPPU JAYAPRAKASH1,2,3, Dr Raj JENA1,4 and.

Compassionate People World Class Care

BRAIN METASTASES.

Figure 2. Kaplan–Meier survival analysis in patients

L M Smyth, P A Rogers, J C Crosbie & J F Donoghue

The dose–response of salvage radiotherapy following radical prostatectomy: A systematic review and meta-analysis Christopher R. King Radiotherapy and.

Junliang Liu, M.D., M.Sc. Ph.D., FRCPC Assistant Professor

Figure 1. (a) Dose distribution of dynamic conformal photon therapy

Table 1 Incidence of metastasis to the esophagus in autopsy cases (1979–88, National Cancer Center Hospital, Tokyo) From: Metastatic Esophageal Tumors.

Figure 1. (a) Regional computed tomography (CT) showed two distinctive patterns of low and iso density mass. (b) Gross finding of the resected specimen.

Figure 1. The (a) anterior–posterior and (b) right-lateral fields and (c, d) the isodose distributions of two axial planes in one patient with T2 stage.

High-Dose-Rate Brachytherapy Boost for Prostate Cancer: Comparison of Two Different Fractionation Schemes Tania Kaprealian, M.D., Vivian Weinberg, Ph.D.,

Dose-escalation patient response.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Concept of the therapeutic index

Radiotherapy for Metastatic Spinal Cord Compression

Figure 5 Schematic illustration of different clinical trial designs

Figures & Tables from the textbook.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Urol. doi: /nrurol

Figure 2 The association between CD8+ T‑cell density of the tumour

Prospective Assessment of Patient-Rated Symptoms Following Whole Brain Radiotherapy for Brain Metastases Edward Chow, MBBS, Lori Davis, PhD, Lori Holden,

External Beam Radiotherapy as Curative Treatment of Prostate Cancer

Eric H. Raabe, Charles G. Eberhart Cancer Cell

Thomas M. Pisansky, MD, Douglas G. Gold, MD, PhD, Keith M

Figure 4 Treatment plans using stereotactic body radiotherapy (SBRT)

Patient-reported symptoms and performance status before palliative radiotherapy in geriatric cancer patients (octogenarians) Carsten Nieder, Thomas A.

Figure 3 The yin and yang of tumour-associated

Figure 1. Non-biochemical recurrence rate for the entire population (n = 122). From: Salvage radiation therapy for prostate cancer patients after prostatectomy.

Figure 2 Host immune responses, not the radiosensitivity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 5 Palliative-care-referral patterns

Surgical Management of Brain Metastases

John M. Varlotto, MD, Abram Recht, MD, John C. Flickinger, MD, Laura N

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Improved Overall Survival with Aggressive Primary Tumor Radiotherapy for Patients with Metastatic Esophageal Cancer David M. Guttmann, MD, MTR, Nandita.

Figure Overview.

Figure Overview.

Stereotactic Body Radiotherapy in Patients with Previous Pneumonectomy: Safety and Efficacy Robert Thompson, MD, Meredith Giuliani, MBBS, Mei Ling Yap,

Effects of chemotherapy and radiotherapy on spermatogenesis in humans

Prophylactic cranial irradiation

Daily nocturnal home hemodialysis

39/69 hormone replacement 9/69 Cerebrovascular events

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

Prognosis of angiosarcoma at different anatomic sites

A protracted ketogenic diet increases radiation response in H292 lung cancer xenografts given conventional fractionated radiation. A protracted ketogenic.

The best response for target lesions per patient for patients with target lesions assessed at baseline and at least 1 follow-up. The best response for.

Stereotactic Body Radiotherapy for Central Lung Tumors

Presentation transcript:

Table 1 Symptoms and signs at presentation From: Prognostic Factors and Therapeutic Options of Radiotherapy in Pediatric Brain Stem Gliomas Jpn J Clin Oncol. 1998;28(8):474-479. doi:10.1093/jjco/28.8.474 Jpn J Clin Oncol | © 1998 Foundation for Promotion of Cancer Research

Table 2 Analysis of variables influencing survival From: Prognostic Factors and Therapeutic Options of Radiotherapy in Pediatric Brain Stem Gliomas Jpn J Clin Oncol. 1998;28(8):474-479. doi:10.1093/jjco/28.8.474 Jpn J Clin Oncol | © 1998 Foundation for Promotion of Cancer Research

Figure 1 The actuarial survival in months of patients with different tumor doses. Broken line, radiation dosage <6600 cGy (n = 14); solid line, dosage ≥6600 cGy (n = 8) (P = 0.0573). From: Prognostic Factors and Therapeutic Options of Radiotherapy in Pediatric Brain Stem Gliomas Jpn J Clin Oncol. 1998;28(8):474-479. doi:10.1093/jjco/28.8.474 Jpn J Clin Oncol | © 1998 Foundation for Promotion of Cancer Research

Figure 2 The actuarial survival in months of patients with different fractionations. Solid line, twice daily HFRT (n = 13); broken line, daily conventional fractionation techniques (n = 9) (P = 0.0615). From: Prognostic Factors and Therapeutic Options of Radiotherapy in Pediatric Brain Stem Gliomas Jpn J Clin Oncol. 1998;28(8):474-479. doi:10.1093/jjco/28.8.474 Jpn J Clin Oncol | © 1998 Foundation for Promotion of Cancer Research

Figure 3 The actuarial survival in months of patients with different tumor grow pattern. Solid line, diffuse lesion (n = 10); broken line, focal lesion (n = 12) (P = 0.017). From: Prognostic Factors and Therapeutic Options of Radiotherapy in Pediatric Brain Stem Gliomas Jpn J Clin Oncol. 1998;28(8):474-479. doi:10.1093/jjco/28.8.474 Jpn J Clin Oncol | © 1998 Foundation for Promotion of Cancer Research

Figure 4 The actuarial survival in months of patients with different symptoms and signs. Solid line, single symptom and sign of cranial neuropathy or long tract sign (n = 10); broken line, both (n = 11)(P = 0.036). From: Prognostic Factors and Therapeutic Options of Radiotherapy in Pediatric Brain Stem Gliomas Jpn J Clin Oncol. 1998;28(8):474-479. doi:10.1093/jjco/28.8.474 Jpn J Clin Oncol | © 1998 Foundation for Promotion of Cancer Research

Figure 5 The actuarial survival in months of patients with (solid line, n = 38) or without (broken line, n = 6) curative management (P < 0.0001). From: Prognostic Factors and Therapeutic Options of Radiotherapy in Pediatric Brain Stem Gliomas Jpn J Clin Oncol. 1998;28(8):474-479. doi:10.1093/jjco/28.8.474 Jpn J Clin Oncol | © 1998 Foundation for Promotion of Cancer Research